Eli Lilly to end 2024 among best in Big Pharma; Novo among worst
As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...
24/7 Wall St21h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...
FDA proposes rule to target asbestos in talc cosmetic products
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Buying from a Compounding Pharmacy
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
KSL1d
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
WASHINGTON — The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for ...
Wyoming News2d
Wyoming Among Minority of States Where Medicaid Doesn't Cover Obesity-Indicated GLP-1s
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Tyler Morning Telegraph2d
Medicaid Now Covers GLP-1s for Obesity in Texas
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Hastings Tribune2d
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
The Mountaineer2d
North Carolina Medicaid Spend on GLP-1s for Obesity up 111% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...